0001209191-21-004458.txt : 20210120 0001209191-21-004458.hdr.sgml : 20210120 20210120180727 ACCESSION NUMBER: 0001209191-21-004458 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210115 FILED AS OF DATE: 20210120 DATE AS OF CHANGE: 20210120 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Klein Lawrence Otto CENTRAL INDEX KEY: 0001762583 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37923 FILM NUMBER: 21539818 MAIL ADDRESS: STREET 1: C/O CRISPR THERAPEUTICS AG STREET 2: 610 MAIN STREET 7TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CRISPR Therapeutics AG CENTRAL INDEX KEY: 0001674416 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 473173478 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 BUSINESS PHONE: 6173154600 MAIL ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-01-15 0 0001674416 CRISPR Therapeutics AG CRSP 0001762583 Klein Lawrence Otto C/O CRISPR THERAPEUTICS, INC. 610 MAIN STREET CAMBRIDGE MA 02139 0 1 0 0 CBO & COO Common Shares 2021-01-15 4 M 0 8666 12.57 A 28666 D Common Shares 2021-01-15 4 S 0 2911 211.44 D 25755 D Common Shares 2021-01-15 4 S 0 2555 212.54 D 23200 D Common Shares 2021-01-15 4 S 0 1200 213.71 D 22000 D Common Shares 2021-01-15 4 S 0 1400 214.46 D 20600 D Common Shares 2021-01-15 4 S 0 400 216.24 D 20200 D Common Shares 2021-01-15 4 S 0 200 217.45 D 20000 D Common Shares 2021-01-15 4 M 0 16344 14.43 A 36334 D Common Shares 2021-01-15 4 S 0 634 212.20 D 35700 D Common Shares 2021-01-15 4 S 0 2800 213.64 D 32900 D Common Shares 2021-01-15 4 S 0 700 214.60 D 32200 D Common Shares 2021-01-15 4 S 0 1500 216.39 D 30700 D Common Shares 2021-01-15 4 S 0 9997 217.42 D 20703 D Common Shares 2021-01-15 4 S 0 701 218.54 D 20002 D Common Shares 2021-01-15 4 S 0 2 219.99 D 20000 D Stock Option (Right to Buy) 12.57 2021-01-15 4 M 0 8666 0.00 D 2026-07-14 Common Shares 8666 0 D Stock Option (Right to Buy) 14.43 2021-01-15 4 M 0 16334 0.00 D 2027-06-14 Common Shares 16334 14666 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $211.01 to $212.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $212.01 to $212.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $213.10 to $214.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.125 to $214.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.15 to $216.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.42 to $217.47, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $212.01 to $212.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $213.48 to $214.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.60 to $214.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.00 to $216.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.22 to $217.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.25 to $218.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.99 to $219.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. 100% of the shares shall vest in 48 equal monthly installments on the thirty-first day of each month, with the first vesting event on October 31, 2016. 100% of the shares shall vest in 48 equal monthly installments on the fifteenth day of each month, with the first vesting event on July 15, 2017. /s/ Michael Esposito, attorney-in-fact 2021-01-20